^
Association details:
| Biomarker: | SQSTM1-NTRK1 fusion |
|---|---|
| Cancer: | Fibrosarcoma |
| Regimen: | (cyclophosphamide + dactinomycin + vincristine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
Excerpt:
The patient was a girl aged 2 years at the time of enrollment with a large sequestosome 1 (SQSTM1)–NTRK1 fusion, localized, infantile fibrosarcoma…She received 4 cycles of VAC and achieved stable disease followed by an initial attempt at a complete surgical resection...Approximately 6 months after completing chemotherapy, she experienced another local disease recurrence.
DOI:
10.1002/cncr.31701
Trial ID:
